A cost–utility analysis of degarelix in the treatment of advanced hormone-dependent prostate cancer in the United Kingdom

References

• National Collaborating Centre for Cancer. Prostate cancer: diagnosis and treatment (CG58) - full guidance. London, UK: National Institute for Health and Clinical Excellence, 2010 . Available at: http://www.nice.org.uk/nicemedia/pdf/CG58NICEGuideline.pdf
   Google Scholar
• Ferlay FJ, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374–403
   PubMed Web of Science ®Google Scholar
• Office for National Statistics. Statistical bulletin: cancer incidence and mortality in the United Kingdom, 2008–2010. UK: Office of National Statistics, 2012. Available at: http://www.ons.gov.uk/ons/rel/cancer-unit/cancer-incidence-and-mortality/2008-2010/stb-cancer-incidence-and-mortality-in-the-united-kindom--2008-2010.html
   Google Scholar
• National Institute for Health and Clinical Excellence. Prostate cancer (hormone refractory) – docetaxel guidance: technology appraisal TA101. London, UK: National Institute for Health and Clinical Excellence, 2006 . Available at: http://www.nice.org.uk/nicemedia/live/11578/33348/33348.pdf
   Google Scholar
• Office for National Statistics. Statistical bulletin: cancer survival in England: patients diagnosed 2006–2010 and followed up to 2011. UK: Office of National Statistics, 2012. Available at: http://www.ons.gov.uk/ons/rel/cancer-unit/cancer-survival/2006---2010--followed-up-to-2011/stb-cancer-survival.html
   Google Scholar
• Heidenreich A, Bastian PJ, Bellmunt J, et al. Guidelines on prostate cancer. Arnhem: European Association of Urology, 2012
   Google Scholar
• Oh WK, Landrum MB, Lamont EB, et al. Does oral antiandrogen use before leuteinizing hormone-releasing hormone therapy in patients with metastatic prostate cancer prevent clinical consequences of a testosterone flare? Urology 2010;75:642–7
   PubMedGoogle Scholar
• Crawford ED, Shore N, Miller K, et al. Degarelix versus LHRH agonists: differential skeletal and urinary tract outcomes from an analysis of six comparative randomized clinical trials. American Society of Clinical Oncology 2013 Genitourinary Cancers Symposium (ASCO-GU). Orlando, FL; 2013
   Google Scholar
• Klotz L, Miller K, Crawford D, et al. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists. Eur Urol 2014; epub ahead of print
   Google Scholar
• Albertsen PC, Klotz L, Tombal B, et al. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol 2014;65:565–73
   PubMed Web of Science ®Google Scholar
• Miller K, Crawford ED, Shore N, et al. Disease control-related outcomes from an analysis of six comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone (LHRH) agonists. 28th Annual European Association of Urology (EAU) Congress. Milan, Italy; 2013
   Google Scholar
• Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 2008;102:1531–8
   PubMed Web of Science ®Google Scholar
• Tombal B, Miller K, Boccon-Gibod L, et al. Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. Eur Urol 2010;57:836–42
   PubMed Web of Science ®Google Scholar
• Porter AT, Ben-Josef E. Humoral mechanisms in prostate cancer: a role for FSH. Urol Oncol 2001;6:131–8
   PubMedGoogle Scholar
• Morote J, Orsola A, Planas J, et al. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol 2007;178:1290–5
   PubMed Web of Science ®Google Scholar
• Radu A, Pichon C, Camparo P, et al. Expression of follicle-stimulating hormone receptor in tumor blood vessels. N Engl J Med 2010;363:1621–30
   PubMed Web of Science ®Google Scholar
• Lu L, Peters J, Roome C, et al. Cost-effectiveness analysis of degarelix for advanced hormone-dependent prostate cancer. BJU Int 2012;109:1183–92
   PubMed Web of Science ®Google Scholar
• Hind T, Hatoum EDC, Nielsen SK, et al. Cost-effectiveness analysis comparing degarelix with leuprolide in hormonal therapy for patients with locally advanced prostate cancer. Expert Rev Pharmacoecon Outcomes Res 2013;13:261–70
   PubMedGoogle Scholar
• Lee D, Gladwell D, Nielsen S, et al. PCN70 The cost effectiveness of Degarelix for the treatment of prostate cancer in the UK. Value Health 2012;15:A421
   Google Scholar
• Fisher D, Brereton N, Tate E. PCN100 a cost-utility analysis of Degarelix in the treatment of advanced hormone-dependent prostate cancer in Scotland. Value Health 2011;14:A452
   Google Scholar
• Scottish Medicines Consortium. Degarelix 120 mg and 80 mg powder and solvent for solution for injection. SMC No. (560/09). Glasgow, UK: Scottish Medicines Consortium, 2010. Available at: http://www.scottishmedicines.org.uk/files/advice/degarelix_Firmagon_RESUBMISSION_FINAL_DECEMBER_2010.doc_for_website.pdf
   Google Scholar
• All Wales Medicines Strategy Group Final Appraisal Recommendation 4112: Degarelix (Firmagon®) 80 mg and 120 mg injection November 2012. Wales, UK: All Wales Medicines Strategy Group, 2012. Available at: http://www.awmsg.org/awmsgonline/app/appraisalinfo/755;jsessionid=00f9e76a1513f2188ea8e896a135
   Google Scholar
• Misra UK, Payne S, Pizzo SV. Ligation of prostate cancer cell surface GRP78 activates a proproliferative and antiapoptotic feedback loop: a role for secreted prostate-specific antigen. J Biol Chem 2011;286:1248–59
   PubMedGoogle Scholar
• Huang SP, Bao BY, Wu MT, et al. Impact of prostate-specific antigen (PSA) nadir and time to PSA nadir on disease progression in prostate cancer treated with androgen-deprivation therapy. Prostate 2011;71:1189–97
   PubMed Web of Science ®Google Scholar
• Crawford ED, Tombal B, Miller K, et al. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. J Urol 2011;186:889–97
   PubMed Web of Science ®Google Scholar
• Crawford E, Shore N, Moul J, et al. Long term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a one-arm crossover from leuprolide to degarelix. Eur Urol 2014;[Accepted]
   Google Scholar
• Hussain M, Goldman B, Tangen C, et al. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol 2009;27:2450–6
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Guide to methods of technology appraisal. London, UK: National Institute for Health and Clinical Excellence, 2013. Available at: http://www.nice.org.uk/media/D45/1E/GuideToMethodsTechnologyAppraisal2013.pdf
   Google Scholar
• Heyns CF. Triptorelin in the treatment of prostate cancer. Clinical Efficacy and Tolerability. Am J Cancer 2005;4:169–83
   Google Scholar
• Seidenfeld J, Samson DJ, Hasselblad V, et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000;132:566–7
   Google Scholar
• Herranz Amo F. Comparative analysis of six months formulation of LHRH analogues for prostate cancer treatment. Arch Espan Urol 2010;63:275–81
   PubMedGoogle Scholar
• Novara G, Galfano A, Secco S, et al. Impact of surgical and medical castration on serum testosterone level in prostate cancer patients. Urol Int 2009;82:249–55
   PubMed Web of Science ®Google Scholar
• Akaza H, Usami M, Koiso K, et al. Long-term clinical study on luteinising hormone-releasing hormone agonist depot formulation in the treatment of stage D prostatic cancer. The TAP-144-SR Study Group. Jpn J Clin Oncol 1992;22:177–84
   PubMedGoogle Scholar
• Ferring Pharmaceuticals Ltd. Gonapeptyl depot 3.75 mg. Summary of product characteristics. Surrey, UK: Datapharm Communications Ltd, 2013. Available at: http://www.medicines.org.uk/emc/medicine/12870/SPC/Gonapeptyl+Depot+3.75+mg/. [Last accessed 26 January 2014]
   Google Scholar
• AstraZeneca UK Ltd. Zoladex® 3.6 mg Implant. Summary of product characteristics. Surrey, UK: Datapharm Communications Ltd, 2013. Available at: http://www.medicines.org.uk/emc/medicine/7855/SPC/Zoladex+3.6mg+Implant/. [Last accessed 26 January 2014]
   Google Scholar
• Takeda UK Ltd. Prostap® 3 DCS 11.25 mg. Summary of product characteristics. Surrey, UK: Datapharm Communications Ltd, 2013. Available at: http://www.medicines.org.uk/emc/medicine/24680/SPC/Prostap+3+DCS/. [Last accessed January 26, 2014]
   Google Scholar
• Office for National Statistics. United Kingdom, Interim Life Tables 2007–09. UK: Office of National Statistics, 2012. Available at: www.ons.gov.uk/ons/publications/re-reference-tables.html?edition=tcm%3A77-61850. [Last accessed 27 January 2014]
   Google Scholar
• National institute for Health and Care Excellence. Final appraisal determination: Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen. London, UK: National Institute for Health and Clinical Excellence, 2012. Available at: www.nice.org.uk/nicemedia/live/13484/59217/59217.pdf. [Last accessed 27 January 2014]
   Google Scholar
• Bayoumi AM, Brown AD, Garber AM. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. J Natl Cancer Inst 2000;92:1731–9
   PubMed Web of Science ®Google Scholar
• All Wales Medicines Strategy Group. AWMSG Secretariat Assessment Report – Advice no. 0612 Abiraterone (Zytiga®) 250 mg tablets. Wales, UK: All Wales Medicines Strategy Group, 2011. Available at: http://www.awmsg.org/awmsgonline/app/appraisalinfo/3. [Last accessed 27 January 2014]
   Google Scholar
• British National Formulary 63. London, UK: BMJ Group and Pharmaceutical Press, 2012. Available at: www.bnf.org. [Last accessed 20 March 2012]
   Google Scholar
• Guest JF, Ruiz FJ, Greener MJ, et al. Palliative care treatment patterns and associated costs of healthcare resource use for specific advanced cancer patients in the UK. Eur J Cancer Care 2006;15:65–73
   PubMedGoogle Scholar
• Personal Social Services Research Unit. Unit Costs of Health and Social Care 2011. Kent, UK: Personal Social Services Research Unit, 2011. Available at: www.pssru.ac.uk/pdf/uc/uc2011/uc2011.pdf. [Last accessed 27 January 2014]
   Google Scholar
• Department of Health. NHS Reference Costs 2010-11. UK: Department of Health, 2011. Available at: https://www.gov.uk/government/publications/2010-11-reference-costs-publication. [Last accessed 27 January 2014]
   Google Scholar
• Gkougkousis E, Oozeerally Z, Allchorne P, et al. 149 The usage of hospital resources by prostate cancer patients in the last year of life. J Urol 2013;189:e61
   Google Scholar
• British National Formulary 59. London, UK: BMJ Group and Pharmaceutical Press, 2011. Available at: www.bnf.org
   Google Scholar
• Curtis L. Unit Costs of Health and Social Care 2008. Kent, UK: Personal Social Services Research Unit, 2008. Available at: http://www.pssru.ac.uk/archive/pdf/uc/uc2008/uc2008.pdf
   Google Scholar
• National Institute for Health and Clinical Excellence. CG75: metastatic spinal cord compression: diagnosis and management of adults at risk of and with metastatic spinal cord compression. London, UK: NICE; 2008
   Google Scholar
• Bennett C, Matchar D, McCrory G, et al. Cost-effective models for Flutamide for prostate carcinoma patients: are they helpful to policy makers? Cancer 1996;77:1854–61
   PubMed Web of Science ®Google Scholar
• Hollingworth W, Gray D, Martin B, et al. Rapid Magnetic Resonance Imaging for diagnosing cancer-related low back pain: a cost-effectiveness analysis. J Gen Intern Med 2003;18:303–12
   PubMedGoogle Scholar
• Iversen P, Damber JE, Malmberg A, et al. Improved outcomes with degarelix monotherapy compared with luteinizing hormone-releasing hormone (LHRH) agonists plus antiandrogen flare protection in the treatment of men with advanced prostate cancer. 29th Congress of the Scandinavian Association of Urologists. Sandefjord, Norway; 2013
   Google Scholar
• Halabi S, Vogelzang NJ, Ou SS, et al. Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer. J Clin Oncol: Official J Am Soc Clin Oncol 2009;27:2766–71
   PubMed Web of Science ®Google Scholar
• Armstrong AJ, Garrett-Mayer E, de Wit R, et al. Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin Cancer Res: Official J Am Assoc Cancer Res 2010;16:203–11
   PubMed Web of Science ®Google Scholar
• Ekman M, Johnell O, Lidgren L. The economic cost of low back pain in sweden in 2001. Acta Orthopaedica 2005;76(2):275-84
   PubMed Web of Science ®Google Scholar